NCT06406465
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity treatment 2 not_yet_recruiting NCT00423254
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. No drug interventions treatment 1 completed NCT00178698
Hyperthermia/Thermal Therapy With Chemotherapy to Treat Inoperable or Metastatic Tumors treatment 2 unknown_status NCT06283719
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer No drug interventions treatment 1 / 2 not_yet_recruiting NCT02038738
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors diagnostic 1 / 2 unknown_status NCT02318784
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers treatment 2 completed NCT03290079
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors treatment 2 completed NCT01866228
Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes No drug interventions supportive_care Not Available completed NCT01578239
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours treatment 3 completed NCT05879978
A Study to Test How Well Different Doses of BI 764532 in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 treatment 1 / 2 recruiting NCT04086485
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET) treatment 1 / 2 recruiting NCT06132113
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers treatment 1 recruiting NCT05882058
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers No drug interventions treatment 2 recruiting NCT03206060
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma treatment 2 recruiting NCT04324502
Mobile Application to Collect PRO Data in NET Patients No drug interventions Not Available Not Available recruiting NCT06240741
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan No drug interventions diagnostic 3 recruiting NCT02315625
Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery treatment 2 terminated NCT06541080
Collection of Liquid Biopsy Samples of Neuroendocrine Neoplasms (NEN) Patients - Collection of NET (CollectNET) 2.0, a Study by the BE-FORCE Consortium No drug interventions Not Available Not Available recruiting NCT05963867
A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine Cancer No drug interventions treatment 1 recruiting NCT02030184
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas treatment 1 / 2 withdrawn NCT04907643
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes No drug interventions supportive_care Not Available recruiting NCT00363051
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy treatment 2 completed NCT02472678
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor No drug interventions treatment Not Available completed NCT00789841
Gastrointestinal Motility in Patients With Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT04073017
Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency No drug interventions supportive_care Not Available terminated NCT00227617
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors treatment 2 / 3 terminated NCT03466216
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET treatment 1 unknown_status NCT01869725
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT diagnostic 2 completed NCT04400474
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study treatment 2 active_not_recruiting NCT05816720
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) Not Available Not Available completed NCT00569127
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor treatment 3 active_not_recruiting NCT03012789
Surgical Intervention and the NETest No drug interventions treatment Not Available active_not_recruiting NCT01476592
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors No drug interventions treatment Not Available completed NCT02628067
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) treatment 2 recruiting NCT02481804
Optimal Feeding for NET Patients No drug interventions treatment Not Available completed NCT03197012
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor treatment 0 completed NCT02092714
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors No drug interventions Not Available Not Available unknown_status NCT01849523
Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study No drug interventions prevention Not Available completed NCT01024387
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors treatment 2 completed NCT01448083
Heart/Mediastinal Ratio Study for Potential Equivalence of Heart/Mediastinal Ratios at One and Two Hours to the Traditional Heart/Mediastinal Ratio Obtained at Four Hours No drug interventions Not Available Not Available unknown_status NCT00131911
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors treatment 2 completed NCT00434109
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization treatment 2 completed NCT04837885
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases treatment 2 recruiting NCT03411915
A Study of XmAb®18087 in Subjects With NET and GIST treatment 1 completed NCT02147106
Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study No drug interventions Not Available Not Available completed NCT00804336
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors treatment 1 completed NCT01048086
90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) treatment 2 withdrawn NCT00165230
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors treatment 2 completed NCT06570174
Oral Protein Supplements for Nutritional and Quality of Life Improvement After Pancreatic Resection in Elderly Patients No drug interventions supportive_care Not Available completed NCT05069220
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor diagnostic 0 recruiting NCT00942682
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors treatment 1 completed NCT02177773
GA-68 DOTA-TOC of Somatostatin Positive Malignancies diagnostic 1 / 2 terminated NCT05749289
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor diagnostic 2 / 3 recruiting NCT01099540
Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor treatment 2 completed NCT02270567
RegisterNET - A Registry for Neuroendocrine Tumors in the USA No drug interventions Not Available Not Available enrolling_by_invitation NCT03143946
DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor No drug interventions treatment Not Available completed NCT00569738
Ga68-DOTA-NOC-PET Imaging of Neuroendocrine Tumors No drug interventions Not Available Not Available unknown_status NCT02882503
Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors No drug interventions treatment Not Available withdrawn NCT01338090
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors Not Available Not Available completed NCT05334290
Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment No drug interventions Not Available Not Available recruiting NCT02375464
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors Not Available Not Available no_longer_available NCT03691064
Post-Authorization Long-Term Safety Study of LUTATHERA Not Available Not Available active_not_recruiting NCT01678664
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors treatment 2 completed NCT02859064
Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres treatment 2 terminated NCT06232564
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs treatment 2 not_yet_recruiting NCT06430021
Study of the Value of hPG80 (Circulating Progastrin) for the Diagnosis of Neuroendocrine Tumours in Patients With an MEN1 Mutation No drug interventions Not Available Not Available recruiting NCT06015802
Predictive Value of Serum and Tissue Molecular Markers and Imaging Features in the Invasiveness and Prognosis of Pituitary Neuroendocrine Tumors No drug interventions Not Available Not Available recruiting NCT06395402
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry treatment 2 recruiting NCT05918302
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. treatment 3 recruiting NCT06345079
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours treatment 2 not_yet_recruiting NCT02174679
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) Not Available Not Available no_longer_available NCT03278379
Avelumab in G2-3 NET treatment 2 unknown_status NCT03673943
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE diagnostic 3 completed NCT04969887
Combination Immunotherapy in Rare Cancers Under InvesTigation treatment 2 active_not_recruiting NCT03220087
Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain No drug interventions Not Available Not Available completed NCT05443087
TARGETed Therapy Drug MONITOring in DIGestive Oncology No drug interventions treatment Not Available recruiting NCT00442533
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors treatment 2 / 3 completed NCT02943733
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs treatment 1 terminated NCT05053854
PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours treatment 1 recruiting NCT03412877
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer treatment 2 recruiting NCT04552847
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors diagnostic 2 / 3 completed NCT06143605
Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT03288597
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms No drug interventions Not Available Not Available unknown_status NCT02754297
Personalized PRRT of Neuroendocrine Tumors treatment 2 active_not_recruiting NCT01524783
Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) treatment 3 completed NCT03728361
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer treatment 2 active_not_recruiting NCT06038461
An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors treatment 1 / 2 not_yet_recruiting NCT01719861
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors treatment 2 terminated NCT01253161
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) treatment 2 completed NCT03136328
Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan diagnostic 3 completed NCT00781911
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer treatment 2 completed NCT03722511
Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs No drug interventions supportive_care 2 completed NCT00978211
DOTA-TOC in Metastasized Neuroendocrine Tumors treatment 2 completed NCT04510311
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors basic_science 0 active_not_recruiting NCT02102893
Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan No drug interventions Not Available Not Available completed NCT01794793
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies treatment 4 completed NCT03935893
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers treatment 2 recruiting NCT05178693
Lutathera and ASTX727 in Neuroendocrine Tumours No drug interventions treatment 1 recruiting NCT03183271
Proton Boost for Locally Advanced HEAD AND NECK TUMORS No drug interventions treatment Not Available completed NCT04804371
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors diagnostic Not Available active_not_recruiting NCT00687778
11C-Acetate PET/CT Non-FDG-Avid Tumors No drug interventions Not Available Not Available unknown_status NCT02691078
Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors No drug interventions diagnostic 2 completed NCT01456078
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors treatment 2 completed NCT01931488
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. No drug interventions diagnostic 2 unknown_status NCT03022188
Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma No drug interventions Not Available Not Available active_not_recruiting NCT02592707
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs treatment 1 / 2 terminated NCT01595009
An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) treatment 4 completed NCT05997056
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors treatment 2 recruiting NCT04440956
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours diagnostic 0 completed NCT03372356
Psychosocial Screening for Neuroendocrine Tumor Patients No drug interventions Not Available Not Available unknown_status NCT04291885
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma treatment 2 recruiting NCT01364415
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) treatment 1 completed NCT01967537
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors diagnostic 2 completed NCT04814732
Expanded Access Program of Surufatinib Not Available Not Available no_longer_available NCT05268952
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment (Liquid-NET 2.0) No drug interventions treatment Not Available recruiting NCT02736500
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors treatment 1 / 2 unknown_status NCT04893759
A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors treatment 1 recruiting NCT03278275
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105 No drug interventions diagnostic 2 completed NCT02838342
Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors other 2 completed NCT04889742
Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors No drug interventions treatment 2 not_yet_recruiting NCT04696042
Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs Not Available Not Available recruiting NCT01590199
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs treatment 1 completed NCT03881306
DEBOXA for Inoperable NET Liver Metastases treatment 1 / 2 unknown_status NCT02348749
18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies No drug interventions diagnostic 1 / 2 active_not_recruiting NCT04296149
Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe No drug interventions diagnostic 2 completed NCT02174549
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer treatment 1 / 2 active_not_recruiting NCT01744249
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas treatment 2 / 3 unknown_status NCT05396118
Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients diagnostic 2 enrolling_by_invitation NCT02743741
Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors treatment Not Available active_not_recruiting NCT04154241
Developing a Method Using PET-MR to Improve Staging and Monitoring of Neuroendocrine Tumor No drug interventions diagnostic Not Available unknown_status NCT03948841
Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences No drug interventions Not Available Not Available completed NCT03289741
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide treatment 4 completed NCT01730417
Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG diagnostic 1 completed NCT04090034
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors No drug interventions Not Available Not Available recruiting NCT05237934
Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) No drug interventions Not Available Not Available recruiting NCT04045834
Study of the Diagnostic Value of Hybrid PET/MR and PET/CT in Neuroendocrine Diseases and Tumor Induced Osteomalacia No drug interventions Not Available Not Available recruiting NCT04119024
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors treatment 1 recruiting NCT02611024
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors treatment 1 / 2 recruiting NCT06505824
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors No drug interventions treatment 1 recruiting NCT01175096
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor treatment 1 / 2 unknown_status NCT01201096
Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) No drug interventions Not Available Not Available unknown_status NCT02455596
Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors treatment 2 unknown_status NCT03478358
Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors treatment 1 unknown_status NCT01262235
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients No drug interventions treatment 1 / 2 completed NCT04074135
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors diagnostic 2 recruiting NCT03454763
Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors No drug interventions treatment 2 unknown_status NCT00747786
Non Interventional Post Marketing Programme in Neuroendocrine Tumours No drug interventions Not Available Not Available completed NCT02134639
PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation No drug interventions Not Available Not Available completed NCT06055439
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy No drug interventions treatment 1 / 2 recruiting NCT04464122
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) Not Available Not Available recruiting NCT03980925
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin. treatment 2 active_not_recruiting NCT03670030
A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System treatment 2 terminated NCT05013957
Neuroendocrine Neoplasms Methylation Based Classifier - The NEMESIs-study No drug interventions Not Available Not Available active_not_recruiting NCT04579757
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT03145857
A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use diagnostic 1 / 2 recruiting NCT00923026
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies No drug interventions Not Available Not Available enrolling_by_invitation NCT00605566
Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors supportive_care 2 completed NCT01619865
Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors diagnostic 1 / 2 completed NCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry No drug interventions Not Available Not Available recruiting NCT00137774
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors treatment 2 completed NCT05871320
Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms No drug interventions diagnostic 0 completed NCT00398320
Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors treatment 2 completed NCT04476082
Nutrition in Gastrointestinal Tumors No drug interventions Not Available Not Available completed NCT01755182
Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors treatment 3 terminated NCT03308682
177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors treatment 1 unknown_status NCT04622631
Using 18F- FDG,18F-DOPA and 68Ga-DOTATATE PET/CT in Detection and Evaluation of Response in Patients With NET Undergoing PRRT No drug interventions Not Available Not Available unknown_status NCT05168631
Multicenter Retrospective Database on Prognostic and Predictive Factors in Patients With Neuroendocrine Tumors No drug interventions Not Available Not Available active_not_recruiting NCT05556473
F-Tryptophan PET/CT in Human Cancers diagnostic 1 recruiting NCT04788927
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study No drug interventions Not Available Not Available not_yet_recruiting NCT03910660
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. treatment 1 / 2 active_not_recruiting NCT05000294
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types treatment 1 / 2 recruiting NCT06155994
68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours treatment 1 / 2 completed NCT05500391
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring No drug interventions health_services_research 2 recruiting NCT02441062
Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors diagnostic 2 completed NCT02678780
Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors treatment 2 completed NCT05160480
A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG No drug interventions Not Available Not Available enrolling_by_invitation NCT00610129
Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) treatment 2 completed NCT03422029
Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients treatment 2 unknown_status NCT04385992
Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET treatment 2 completed NCT05459844
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs treatment 3 active_not_recruiting NCT03079440
TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors treatment 2 completed NCT01970540
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors treatment 1 completed NCT00501540
Lithium for Low-Grade Neuroendocrine Tumors treatment 2 completed NCT00947167
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors treatment 2 terminated NCT02267967
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors treatment 1 completed NCT06356467
Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs No drug interventions Not Available Not Available recruiting NCT02568267
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) treatment 2 active_not_recruiting NCT04375267
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours treatment 1 active_not_recruiting NCT04444401
Registry on NEN Patients and COVID-19 No drug interventions Not Available Not Available recruiting NCT03070301
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors treatment 2 completed NCT02489604
Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors treatment 2 active_not_recruiting NCT00851604
ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors No drug interventions Not Available Not Available unknown_status NCT04438304
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO) diagnostic 2 active_not_recruiting NCT05199272
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies No drug interventions treatment 1 / 2 active_not_recruiting NCT01234168
A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea No drug interventions Not Available Not Available completed NCT00037869
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors treatment 3 completed NCT05513469
Biomarker Identification of Radionuclide Therapy-induced Radiation Responses basic_science Not Available recruiting NCT00985946
Study of Panobinostat in Patients With Neuroendocrine Tumors treatment 2 terminated NCT04331912
PFS and OS of Patients With Advanced Neuroendocrine Cancer (NEN) After Systemic Treatment No drug interventions Not Available Not Available unknown_status NCT04706910
18F-DOPA II - PET Imaging Optimization diagnostic 3 recruiting NCT04197310
Cabozantinib and Nivolumab for Carcinoid Tumors treatment 2 completed NCT05475210
177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors treatment 1 recruiting NCT06122610
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors treatment 1 not_yet_recruiting NCT05967481
Evaluation of Study Experiences of Neuroendocrine Tumor Patients No drug interventions Not Available Not Available not_yet_recruiting NCT03271281
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2 No drug interventions diagnostic 2 completed NCT03749681
Neuroendocrine Tumors of Old Patients in the West of France No drug interventions Not Available Not Available unknown_status NCT04888481
68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors diagnostic 2 recruiting NCT06402695
Observational Study on GEP-and Pulm-NET Treated at FPG No drug interventions Not Available Not Available recruiting NCT05249114
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors treatment 1 active_not_recruiting NCT01218555
Study of Everolimus (RAD001) in Combination With Lenalidomide treatment 1 completed NCT05113355
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm treatment 2 recruiting NCT04365023
Cohort of Well-differentiated Grade 3 Neuroendocrine Digestive Tumors Not Available Not Available completed NCT02936323
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers treatment 1 / 2 completed NCT00424723
Pemetrexed in Patients With Advanced Neuroendocrine Tumors treatment 2 completed NCT06456723
Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours. No drug interventions diagnostic 1 / 2 completed NCT04584008
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics No drug interventions treatment Not Available recruiting NCT02507908
5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor' No drug interventions Not Available Not Available completed NCT01115803
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors treatment 1 terminated NCT06211803
Clinical Application of the Prototype J-PET Device No drug interventions Not Available Not Available completed NCT02489903
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) treatment 2 completed NCT05554003
Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study treatment 2 recruiting NCT05387603
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. treatment 3 recruiting NCT03420521
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors treatment 2 terminated NCT02589821
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors treatment 3 completed NCT03288402
Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients No drug interventions screening Not Available completed NCT04713202
Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl supportive_care 2 withdrawn NCT02279602
Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study treatment 2 completed NCT05077384
Open-label Study of Surufatinib in Japanese Patients treatment 1 / 2 active_not_recruiting NCT04028479
The Registry of Oncology Outcomes Associated With Testing and Treatment No drug interventions Not Available Not Available recruiting NCT05922579
A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET No drug interventions Not Available Not Available terminated NCT04427787
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET treatment 2 unknown_status NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies No drug interventions treatment 1 recruiting NCT05255133
A Study to Evaluate the Value of Circulating Tumour DNA in Follow-up of Patients With an Advanced Gastroenteropancreatic or Lung Neuroendocrine Tumour Under Everolimus +- SSA Treatment No drug interventions treatment Not Available completed NCT02539433
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) No drug interventions diagnostic Not Available completed NCT03600233
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors treatment 2 active_not_recruiting NCT02939651
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors treatment 2 completed NCT04491851
Impact of Peptides and Chelators on Somatostatin Receptor Antagonists No drug interventions diagnostic 2 unknown_status NCT03167853
Study of JS001 in Patients With Advanced Neuroendocrine Tumors treatment 1 completed NCT03629847
Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue treatment 1 / 2 unknown_status NCT04034745
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain Not Available Not Available withdrawn NCT04544098
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver treatment 0 active_not_recruiting NCT03130205
Biomarker Study in Pancreatic Neuroendocrine Tumours No drug interventions Not Available Not Available unknown_status NCT04847505
68Ga-DOTA-TATE PET/CT Imaging in NETs No drug interventions diagnostic 3 recruiting NCT04276597
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. treatment 2 withdrawn NCT03217097
MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents treatment Not Available completed NCT03014297
Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression treatment 1 terminated NCT04318561
Gallium-68 Labeled LM3 PET/CT in Neuroendocrine Tumors No drug interventions diagnostic 1 / 2 completed NCT03583528
DOTATOC PET/CT for Imaging NET Patients No drug interventions Not Available Not Available recruiting NCT01099228
Combination Targeted Radiotherapy in Neuroendocrine Tumors No drug interventions treatment Not Available completed NCT04029428
Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression treatment 2 unknown_status NCT04152928
Applying PET/MR in Neuroendocrine Tumors - Imaging Dynamic Processes in Both Modalities No drug interventions diagnostic Not Available unknown_status NCT04085211
Image-Enhanced Endoscopy in the Gastrointestinal Tract No drug interventions Not Available Not Available unknown_status NCT00056693
Treatment With SU11248 in Patients With Neuroendocrine Tumors treatment 2 completed NCT03986593
Cryoablation of Bone Metastases From Endocrine Tumors No drug interventions treatment Not Available terminated NCT05709171
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms diagnostic 2 enrolling_by_invitation NCT01215578
Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors treatment 2 terminated NCT06472388
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors treatment 2 recruiting NCT03211988
Entinostat Neuroendocrine (NE) Tumor treatment 2 terminated NCT02067988
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study No drug interventions treatment 2 completed NCT06263088
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer. No drug interventions supportive_care Not Available not_yet_recruiting NCT06344507
Iconographic Registry of Pancreatobiliary Endoscopy Procedures No drug interventions Not Available Not Available recruiting NCT03724409
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases treatment 0 terminated NCT04140409
Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation treatment 4 terminated NCT03037385
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors treatment 1 / 2 completed NCT01317615
RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation treatment 4 completed NCT04644315
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors treatment 2 terminated NCT06540937
Phase II Clinical Study of Leflunomide in the Treatment of MEN-1 Neuroendocrine Tumor treatment 2 recruiting NCT02609737
Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors No drug interventions treatment Not Available completed NCT04848337
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer treatment 2 recruiting NCT04780737
Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis No drug interventions Not Available Not Available completed NCT04334837
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) No drug interventions Not Available Not Available approved_for_marketing NCT05427032
HRQoL During PRRT in Patients With NETs No drug interventions Not Available Not Available completed NCT04432532
Neuroendocrine and Adrenal Tumors No drug interventions Not Available Not Available not_yet_recruiting NCT00657332
Clinical and Pathologic Studies in Neuroendocrine Tumors No drug interventions Not Available Not Available withdrawn NCT06121752
Device Assisted Full Thickness Resection Versus Endoscopic Submucosal Dissection for Duodenal Neuroendocrine Tumors No drug interventions treatment Not Available recruiting NCT02810600
Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors No drug interventions Not Available Not Available completed NCT02359500
68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs) diagnostic 1 terminated NCT05255159
Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors No drug interventions diagnostic 2 recruiting NCT06204159
Lipiodol Deposition Using Endhole vs. Pressure-Modulated Delivery No drug interventions other Not Available recruiting NCT05680675
Dual-Tracer Theranostic PET No drug interventions diagnostic Not Available completed NCT02588170
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors treatment 3 completed NCT03335670
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors diagnostic 0 active_not_recruiting NCT03873870
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors No drug interventions diagnostic Not Available completed NCT04897542
Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors diagnostic 0 recruiting NCT03870399
Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression treatment 2 completed NCT02012699
Integrated Cancer Repository for Cancer Research No drug interventions Not Available Not Available recruiting NCT04166006
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. treatment 2 recruiting NCT01398306
Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. No drug interventions Not Available Not Available completed NCT02840149
SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors basic_science 3 completed NCT00050349
EPO906 in Carcinoid and Other Neuroendocrine Tumors treatment 2 completed NCT01135849
B-Receptor Signaling in Cardiomyopathy No drug interventions Not Available Not Available completed NCT01290536
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases No drug interventions treatment 2 completed NCT04339036
CapTemY90 for Grade 2 NET Liver Metastases treatment 2 recruiting NCT04362436
TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets No drug interventions treatment 2 recruiting NCT00227136
Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion No drug interventions diagnostic 3 terminated NCT06148636
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors No drug interventions treatment 0 active_not_recruiting NCT02705313
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx Not Available Not Available approved_for_marketing NCT03190213
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma treatment 2 terminated NCT02358018
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial Not Available Not Available no_longer_available NCT05636618
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors No drug interventions treatment 1 / 2 recruiting NCT05693519
GastroIntestinal Cancer in Children and Adolescents No drug interventions Not Available Not Available active_not_recruiting NCT05246319
Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors No drug interventions Not Available Not Available unknown_status NCT06242119
Clinical Application of the J-PET Scanner Prototype No drug interventions Not Available Not Available recruiting NCT03590119
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases treatment 2 / 3 completed NCT03042416
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety No drug interventions diagnostic 3 completed NCT06041516
Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas No drug interventions treatment 1 recruiting NCT06300216
A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors Not Available Not Available not_yet_recruiting NCT06455358
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) No drug interventions diagnostic 1 / 2 not_yet_recruiting NCT02355535
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 treatment 1 completed NCT00780663
Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma treatment 2 completed NCT03895463
Study to Assess the Use of Lanreotide Autogel® 120 mg in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) in Routine Clinical Practice No drug interventions Not Available Not Available withdrawn NCT04488263
Natural History Study of Children and Adults With Neuroendocrine Neoplasms (NEN)s No drug interventions Not Available Not Available terminated NCT05894486
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors treatment 2 not_yet_recruiting NCT05076786
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma treatment 2 recruiting NCT04336839
Portal Vein Resection in Pancreatic Neuroendocrine Tumours No drug interventions Not Available Not Available unknown_status NCT06485739
Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma treatment 4 not_yet_recruiting NCT04066322
Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment No drug interventions Not Available Not Available recruiting NCT02246322
A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions. No drug interventions diagnostic Not Available unknown_status NCT01039922
SwissNET - a Registry for Neuroendocrine Tumours in Switzerland No drug interventions Not Available Not Available recruiting NCT04194125
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer treatment 2 unknown_status NCT01873248
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective diagnostic 0 completed NCT01237457
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms treatment 2 completed NCT03923257
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents treatment 1 / 2 withdrawn NCT01163526
Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies No drug interventions Not Available Not Available terminated NCT04919226
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE treatment 3 recruiting NCT04614766
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors treatment 1 / 2 withdrawn NCT05565066
A Real-world Comparison of FNB and FNA in IHC-required Lesions. No drug interventions Not Available Not Available completed NCT03095274
Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin treatment 2 completed NCT02125474
Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate No drug interventions treatment Not Available completed NCT03840720
The Patient's Journey - the Time to Final Diagnosis in Patients With SiNET No drug interventions Not Available Not Available completed NCT06159920
Evaluation of the Diagnostic and Prognostic Role of PET (PET/CT and PET/MRI) in Neuroendocrin Tumors. No drug interventions Not Available Not Available recruiting NCT04954820
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET treatment 2 recruiting NCT00815620
Best Therapy for Patients With Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT04041882
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor diagnostic 0 unknown_status NCT04949282
Spanish Series of Patients Treated With the Radionuclide Lutetium177 Not Available Not Available recruiting NCT03689231
Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs). No drug interventions Not Available Not Available unknown_status NCT05804331
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study No drug interventions Not Available Not Available recruiting NCT02749331
Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy No drug interventions treatment 1 / 2 unknown_status NCT00843531
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors treatment 2 terminated NCT00171873
Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut treatment 3 completed NCT02246127
Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced Pancreatic Neuroendocrine Tumor (pNET) treatment 3 completed NCT05477576
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy treatment 3 recruiting NCT03883776
Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors diagnostic 1 completed NCT05987176
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases treatment 2 recruiting NCT04672876
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors treatment 2 withdrawn NCT06045260
"Receptor Radionuclide Therapy With 177Lu-DOTATOC treatment 2 recruiting NCT00953394
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors treatment 2 completed NCT03112694
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT02823691
The MetNET-2 Trial treatment 0 unknown_status NCT03562091
Perception of Information and Quality of Life in Neuroendocrine Tumour on Lanreotide Autogel No drug interventions Not Available Not Available completed NCT02402062
A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours treatment 2 completed NCT02838862
Identification of Biomarker Profiles GEP-NEN Patients No drug interventions Not Available Not Available unknown_status NCT05017662
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072 No drug interventions other Not Available active_not_recruiting NCT06056362
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors No drug interventions diagnostic 1 / 2 recruiting NCT04207762
18F-AmBF3-TATE PET/CT for Imaging NET Patients No drug interventions Not Available Not Available completed NCT04753229
Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia No drug interventions Not Available Not Available completed NCT04104529
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department No drug interventions other Not Available recruiting NCT02299089
Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) treatment 2 completed NCT03049189
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients treatment 3 active_not_recruiting NCT06321692
Early Identification of Cardiac Involvement in Patients With Carcinoid: Clinical and Prognostic Implications No drug interventions diagnostic Not Available recruiting NCT04258592
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors diagnostic 1 terminated NCT04915144
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs treatment 2 withdrawn NCT02586844
Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT02646644
Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis No drug interventions Not Available Not Available completed NCT03576040
Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors No drug interventions Not Available Not Available unknown_status NCT04831567
Study of MIBG-I131 in Patients With Well Differentiated Neuroendocrine Tumors No drug interventions treatment 2 withdrawn NCT04922801
Optimising Molecular Radionuclide Therapy No drug interventions Not Available Not Available completed NCT03279601
Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor treatment 2 unknown_status NCT03834701
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms No drug interventions treatment Not Available completed NCT06358001
EchoTip AcuCore Post-Market Clinical Study No drug interventions Not Available Not Available recruiting NCT04017104
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging No drug interventions Not Available Not Available unknown_status NCT02973204
Circulating Tumor Cells and Tumor DNA in HCC and NET Not Available Not Available completed NCT01469572
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases treatment 1 completed NCT05153772
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients treatment 2 active_not_recruiting NCT04077372
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers No drug interventions supportive_care Not Available terminated NCT02132468
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers treatment 2 completed NCT02815969
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors No drug interventions Not Available Not Available completed NCT03273712
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) treatment 2 completed NCT03083210
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET treatment 4 unknown_status NCT04543955
Telotristat With Lutathera in Neuroendocrine Tumors treatment 2 terminated NCT04129255
Octreotide LAR in the Induction of Immunologic Response in NENs Patients treatment 2 completed NCT05064150
Neuroendocrine Tumors - Patient Reported Outcomes No drug interventions Not Available Not Available enrolling_by_invitation NCT00869050
Capecitabine and Temozolomide for Neuroendocrine Cancers treatment 2 completed NCT05870423
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors treatment 1 recruiting NCT04524208
A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 treatment 2 active_not_recruiting NCT04790708
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2) No drug interventions treatment Not Available unknown_status NCT06448208
Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors No drug interventions Not Available Not Available recruiting NCT05746208
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors treatment 2 recruiting NCT04123262
Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression treatment 2 recruiting NCT02441088
Theranostics: 68GaDOTATOC and 90YDOTATOC treatment 2 active_not_recruiting NCT00627198
The Safety and Efficacy of CPTK787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors treatment 2 completed NCT03592940
The Management of Neuroendocrine Tumours: A Nutritional Viewpoint. No drug interventions Not Available Not Available completed NCT02788578
A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours No drug interventions Not Available Not Available terminated NCT03958188
PreOPerative Imaging of NeuroEndocrine Tumors No drug interventions Not Available Not Available unknown_status NCT02075606
Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients diagnostic 4 completed NCT00323076
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours diagnostic 1 / 2 terminated NCT02698410
Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors. treatment 2 completed NCT04579679
Open-Label Surufatinib in European Patients With NET treatment 2 active_not_recruiting NCT01673906
68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours No drug interventions diagnostic 2 completed NCT01840449
Somatuline Predictive Factors in Acromegaly and NET Not Available Not Available completed NCT02923934
A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers treatment 2 completed NCT04452396
CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia No drug interventions diagnostic Not Available terminated NCT00326469
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours treatment 2 completed NCT02831179
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor treatment 1 withdrawn NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT02817945
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging No drug interventions diagnostic 0 unknown_status NCT03950609
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors treatment 2 active_not_recruiting NCT02399215
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors treatment 2 completed NCT03001349
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors diagnostic 0 terminated NCT03734913
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors No drug interventions treatment 1 unknown_status NCT03457948
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases treatment 2 active_not_recruiting NCT02402920
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer treatment 1 active_not_recruiting NCT06523582
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients No drug interventions Not Available Not Available recruiting NCT04720391
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET) No drug interventions Not Available Not Available unknown_status NCT03511768
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms diagnostic 1 / 2 unknown_status NCT05879055
A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN treatment 2 recruiting NCT04917484
Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients No drug interventions treatment 2 recruiting NCT04750954
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors treatment 1 active_not_recruiting NCT06343428
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients No drug interventions Not Available Not Available recruiting NCT04927611
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm No drug interventions Not Available Not Available unknown_status NCT05165407
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC treatment 2 recruiting NCT06276309
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors No drug interventions Not Available Not Available recruiting NCT03375320
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors treatment 3 active_not_recruiting NCT04459273
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers basic_science 1 recruiting NCT06337760
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs. No drug interventions Not Available Not Available recruiting NCT02402244
Project: Every Child for Younger Patients With Cancer No drug interventions Not Available Not Available recruiting NCT04931446
Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis No drug interventions Not Available Not Available unknown_status NCT01763554
Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014 Not Available Not Available active_not_recruiting NCT04525638
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours treatment 2 recruiting NCT04649580
United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting No drug interventions Not Available Not Available completed NCT05673031
68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors No drug interventions Not Available Not Available recruiting